



AMENDMENT TRANSMITTAL LETTER					Docket No. 1781-0215P
Application No. 09/766,412-Conf. #7335		Filing Date January 22, 2001		Examiner A. A. Moham	Art Unit ed 1654
pplicant(s): Ruowen GE et al.					
nvention: SMALL PEPTIDES HAVING ANTI-ANGIOGENIC AND ENDOTHELIAL CELL INHIBITION ACTIVITY					
AS Amendment Commissioner for I P.O. Box 1450 Alexandria, VA 223 Transmitted here	313-1450 with is an ame			• •	
The fee has been calculated and is transmitted as shown below.					
	Claims Remaining After	Highest Number Previously	Number Extra Claims		
Total Claims	Amendment 19	- 20 =	Present	Rate X	
Independent Claims	2	- 3 =		х	
Multiple Dependent Claims (check if applicable)					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT: 0.00					
x Large Entity Small Entity					
x No additional fee is required for this amendment.					
Please charge Deposit Account No in the amount of \$ A duplicate copy of this sheet is enclosed.					
A check in the amount of \$ is enclosed.					
Payment by credit card. Form PTO-2038 is attached.					
x The Director is hereby authorized to charge and credit Deposit Account No02-2448 as described below. A duplicate copy of this sheet is enclosed.					
x Credit any overpayment.					
x Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
Dated: August 23, 2006					
Mark J. Well Attorney Reg. 1	No.: 36,623				
BIRCH, STEWART, KOLASCH & BIRCH, LLP 8110 Gatehouse Road Suite 100 East P.O. Box 747 Falls Church, Virginia 22040-0747 (703) 205-8043					



Docket No.: 1781-0215P

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ruowen GE et al.

Application No.: 09/766,412

Confirmation No.: 7335

Art Unit: 1654 Filed: January 22, 2001

For: SMALL PEPTIDES HAVING ANTI-

ANGIOGENIC AND ENDOTHELIAL CELL

INHIBITION ACTIVITY

Examiner: A. A. MOHAMED

AMENDMENT UNDER 37 CFR 1.111

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated June 13, 2006, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.